CDK9 and mature T-cell and NK-cell non-Hodgkin lymphoma: In contrast, SNS-032, a non-covalent pan-CDK inhibitor (with CDK9 and CDK7 IC50=4 and 62 nM, respectively)8 was less potent and active across our PTCL cell line panel; in fact OCI-Ly12, the prototypical PTCL-NOS cell line, was resistant to this compound.